Houston, Texas 77030


Purpose:

This trial studies how well repetitive transcranial magnetic stimulation (rTMS) works in improving neuropathy due to oxaliplatin chemotherapy in patients with stage I-IV cancer. rTMS is designed to change brain activity by introducing small magnetic impulses to the scalp that encourage the brain to change its activity.


Study summary:

PRIMARY OBJECTIVES: I. Examine the effects of the repetitive transcranial magnetic stimulation (rTMS) training program on perceptions of chemotherapy-induced peripheral neuropathy (CIPN) versus placebo (PC) and wait-list control groups (WLC). SECONDARY OBJECTIVES: I. Explore changes in cortical activity: Electroencephalography (EEG) brain maps (low resolution electromagnetic tomography) will be assessed over time and compared between groups. II. Determine if rTMS improves other aspects of CIPN, quality of life (QOL), and mental health (MH) compared to PC and WLC. III. Explore moderators/mediators of the intervention by examining the extent to which changes in EEG patterns mediate the effects of the intervention and the extent to which there are interaction effects of the intervention and each of the baseline brain regions. OUTLINE: Patients are randomized to 1 of 3 groups. GROUP I: Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days. GROUP II: Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days. GROUP III: Patients receive standard of care. After completion of study, patients are followed up within 1 week and at 1 month.


Criteria:

Inclusion Criteria: - Patients with stage I-IV cancers who received oxaliplatin chemotherapy - Understand and read English, sign a written informed consent, and be willing to follow protocol requirements - Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 - Grade 2 or higher neuropathic symptoms according to the National Cancer Institute's 4 point grading scale - Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician) - Patients must have neuropathic symptoms for a minimum of 3 months - No plans to change the type of pain medication (if a patient is on pain medication) - Willing to come to MD Anderson for the therapy sessions Exclusion Criteria: - Patients who are taking any antipsychotic medications - Patients who have evidence of brain metastases or any with any active central nervous system (CNS) disease at their time of entry into the trial - Patients who have ever been diagnosed with bipolar disorder or schizophrenia - Patients who have a history of head injury, focal brain lesions, or known seizure activity - Patients who are withdrawing from drugs - Patients with intracranial implants or a cardiac pacemaker or any device that is not considered magnetic resonance imaging (MRI) safe. Colorectal patients are sometimes prescribed Tramadol to help control the symptoms of CIPN. Tramadol does lower the seizure threshold, however these patients will be considered eligible for the study if they discontinue the drug 48 hours before the baseline and do not use it during the duration of the study


NCT ID:

NCT03219502


Primary Contact:

Principal Investigator
Sarah Prinsloo
M.D. Anderson Cancer Center

Sarah Prinsloo
Phone: 713-563-9627
Email: sprinsloo@mdanderson.org


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States

Sarah Prinsloo
Phone: 713-563-9627

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.